Clinical trials: Drug Therapy, Combination
Neuroendocrine Tumors
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib…
- Trial name
- PELICAN (NCT06232564)
- Testing
- Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children
Cohort I: The purpose of this study is to see how safe it is to combine 2 anti-HIV medications, efavirenz (EFZ) and nelfinavir (NFV) to treat HIV-positive children and to find an appropriate dose of EFZ to use in combination with…
- Trial name
- NCT00000893
- Testing
- Nelfinavir mesylate, Efavirenz
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 103 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
This clinical trial was done to show whether a radioactive drug (I-131-1095) that binds to prostate-specific membrane antigen (PSMA) is useful in treating metastatic prostate cancer that is positive for PSMA.
- Conditions
- Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate
- Trial name
- ARROW (NCT03939689)
- Testing
- I-131-1095, Enzalutamide
- Where
- 27 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Liver Metastasis Colon Cancer, Synchronous Neoplasm
Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including…
- Trial name
- NCT05362825
- Testing
- Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery
- Where
- Vietnam
- Volunteers
- 89 people
- Sponsor
- Cho Ray Hospital
Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
This is a multicenter, 2-arm open-label, randomized comparative phase II study in each of two separate cohorts (non-squamous NSCLC and squamous NSCLC) according to histology.
- Trial name
- SOLUTION (NCT03319316)
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rectal Cancer
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase II pilot study of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy for patients with locally advanced rectal carcinoma
- Trial name
- NCT01434147
- Testing
- preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
- Where
- 7 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
HIV Infections
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior…
- Trial name
- NCT00000838
- Testing
- Lamivudine, Stavudine, Zidovudine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 256 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 24 of study therapy.
- Trial name
- NCT00002378
- Testing
- Ritonavir, Nelfinavir mesylate, Saquinavir
- Where
- 102 sites in United States, Germany and 4 more
- Volunteers
- 825 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer
Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00008047
- Testing
- fluorouracil, hydroxyurea, paclitaxel
- Where
- 14 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoma, Non-Small-Cell Lung
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
The main purpose of the study was to evaluate the safety and tolerability of M7824 in combination with chemotherapy.
- Trial name
- NCT03840915
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 19 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma
This is a phase III, multi-Center, randomized, placebo-controlled trial to investigate the efficacy and safety of CS1001 in combination with Oxaliplatin and Capecitabine (CAPOX) chemotherapy in first-line subjects with…
- Trial name
- NCT03802591
- Testing
- CS1001 monoclonal antibody, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 479 people
- Sponsor
- CStone Pharmaceuticals
Squamous Cell Carcinoma of Head and Neck
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
This is a prospective, single center phase II clinical study with a planned enrollment of 33 patients. The main objective is to evaluate the efficacy and safety of the PD-1 inhibitor toripalimab combined with cetuximab…
- Trial name
- NCT06081582
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Small Cell Lung Cancer ( SCLC )
A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy
A single-arm exploratory clinical study to observe and evaluate the first-line treatment of elderly and treatment-intolerant patients with small cell lung cancer using benmelstobart in combination with anlotinib and etoposide.
- Trial name
- SCLC (NCT07728955)
- Testing
- benmelstobart in combination with anlotinib and etoposide
- Volunteers
- 64 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Urologic Neoplasms, Metastatic Bladder Cancer
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled…
- Conditions
- Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
- Trial name
- NCT01454089
- Testing
- OGX-427 600 mg, OGX-427 1000 mg, Gemcitabine
- Where
- 55 sites in United States, Canada and 5 more
- Volunteers
- 183 people
- Sponsor
- Achieve Life Sciences
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC
Advanced Hepatocellular Carcinoma, Carcinoma
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT01214343
- Testing
- Sorafenib with Low-dose FP, Sorafenib
- Where
- 30 sites in Japan
- Volunteers
- 190 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Esophageal Cancer, Squamous Cell, Cetuximab Effect
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, randomized, controlled trial. At the end of a 28-day screening period, all eligible subjects will be randomly assigned into treatment Arm A or B in a 1:1 ratio.
- Conditions
- Esophageal Cancer, Squamous Cell, Cetuximab Effect, Chemotherapy Effect
- Trial name
- NCT03126708
- Testing
- cetuximab, cisplatin plus paclitaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University
Multiple Myeloma
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT00773747
- Testing
- Vorinostat, bortezomib
- Volunteers
- 637 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Unresectable Solid Tumors
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable…
- Trial name
- NCT04894825
- Testing
- M108
- Where
- China
- Volunteers
- 152 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Esophageal Cancer
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer
Esophageal cancer is one of the common malignant disease, especially in China. The annual incidence of esophageal squamous cell carcinoma is 260,000 with the motility of 210,000. The prognosis of esophageal cancer is very poor.
- Trial name
- NCT01704690
- Testing
- S-1 and Paclitaxel, Paclitaxel and Cisplatin, 5-FU and Cisplatin
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Peking University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.